Kamilia Abdelraouf1, Safa Almarzoky Abuhussain1,2, David P Nicolau1,3. 1. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. 2. Umm Al-Qura University, Makkah, Saudi Arabia. 3. Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.
Abstract
OBJECTIVES: Cefepime/taniborbactam is a cephalosporin/cyclic boronate β-lactamase inhibitor combination under development for the treatment of infections due to MDR Enterobacterales and Pseudomonas aeruginosa. Using a neutropenic murine thigh infection model, we aimed to determine the pharmacokinetic/pharmacodynamic index, relative to taniborbactam exposure, that correlated most closely with the efficacy of the cefepime/taniborbactam combination and the magnitude of index required for efficacy against serine-β-lactamase-producing strains. METHODS: Twenty-six clinical Enterobacterales (expressing ESBLs, plasmid-mediated AmpC and/or carbapenemases of classes A or D; cefepime/taniborbactam combination MICs 0.06-16 mg/L) and 11 clinical P. aeruginosa (AmpC overproducing or KPC expressing; cefepime/taniborbactam combination MICs 1-16 mg/L) were evaluated. A cefepime human-simulated regimen (HSR) equivalent to a clinical dose of 2 g q8h as a 2 h infusion was given in combination with taniborbactam for 24 h. For a subset of P. aeruginosa isolates, a sub-therapeutic cefepime exposure was utilized. RESULTS: Dose-fractionation studies revealed that dosing frequency had no impact on taniborbactam potentiation of cefepime activity. Relative to the initial bacterial burden, the median taniborbactam fAUC0-24/MIC associated with 1 log kill in combination with the cefepime HSR for Enterobacterales and P. aeruginosa isolates was 2.62 and 0.46, respectively. In combination with sub-therapeutic cefepime, the median taniborbactam fAUC0-24/MIC associated with 1 and 2 log kill against AmpC-overproducing P. aeruginosa was 2.00 and 3.30, respectively, relative to the bacterial burden in the cefepime-treated groups. The taniborbactam HSR (equivalent to 0.5 g q8h as a 2 h infusion) was adequate to attain ≥1 log reduction against all test isolates. CONCLUSIONS: Our data show that the cefepime/taniborbactam combination (2 g/0.5 g q8h as a 2 h infusion) exerts potent in vivo activity against cefepime-resistant isolates, including serine-carbapenemase producers.
OBJECTIVES:Cefepime/taniborbactam is a cephalosporin/cyclic boronate β-lactamase inhibitor combination under development for the treatment of infections due to MDR Enterobacterales and Pseudomonas aeruginosa. Using a neutropenicmurine thigh infection model, we aimed to determine the pharmacokinetic/pharmacodynamic index, relative to taniborbactam exposure, that correlated most closely with the efficacy of the cefepime/taniborbactam combination and the magnitude of index required for efficacy against serine-β-lactamase-producing strains. METHODS: Twenty-six clinical Enterobacterales (expressing ESBLs, plasmid-mediated AmpC and/or carbapenemases of classes A or D; cefepime/taniborbactam combination MICs 0.06-16 mg/L) and 11 clinical P. aeruginosa (AmpC overproducing or KPC expressing; cefepime/taniborbactam combination MICs 1-16 mg/L) were evaluated. A cefepimehuman-simulated regimen (HSR) equivalent to a clinical dose of 2 g q8h as a 2 h infusion was given in combination with taniborbactam for 24 h. For a subset of P. aeruginosa isolates, a sub-therapeutic cefepime exposure was utilized. RESULTS: Dose-fractionation studies revealed that dosing frequency had no impact on taniborbactam potentiation of cefepime activity. Relative to the initial bacterial burden, the median taniborbactam fAUC0-24/MIC associated with 1 log kill in combination with the cefepime HSR for Enterobacterales and P. aeruginosa isolates was 2.62 and 0.46, respectively. In combination with sub-therapeutic cefepime, the median taniborbactam fAUC0-24/MIC associated with 1 and 2 log kill against AmpC-overproducing P. aeruginosa was 2.00 and 3.30, respectively, relative to the bacterial burden in the cefepime-treated groups. The taniborbactam HSR (equivalent to 0.5 g q8h as a 2 h infusion) was adequate to attain ≥1 log reduction against all test isolates. CONCLUSIONS: Our data show that the cefepime/taniborbactam combination (2 g/0.5 g q8h as a 2 h infusion) exerts potent in vivo activity against cefepime-resistant isolates, including serine-carbapenemase producers.
Authors: Anthony M Nicasio; Robert E Ariano; Sheryl A Zelenitsky; Aryun Kim; Jared L Crandon; Joseph L Kuti; David P Nicolau Journal: Antimicrob Agents Chemother Date: 2009-02-02 Impact factor: 5.191
Authors: Mark J Siedner; Alicia Galar; Belisa B Guzmán-Suarez; David W Kubiak; Nour Baghdady; Mary Jane Ferraro; David C Hooper; Thomas F O'Brien; Francisco M Marty Journal: Clin Infect Dis Date: 2014-03-18 Impact factor: 9.079
Authors: Jodie C Hamrick; Jean-Denis Docquier; Tsuyoshi Uehara; Cullen L Myers; David A Six; Cassandra L Chatwin; Kaitlyn J John; Salvador F Vernacchio; Susan M Cusick; Robert E L Trout; Cecilia Pozzi; Filomena De Luca; Manuela Benvenuti; Stefano Mangani; Bin Liu; Randy W Jackson; Greg Moeck; Luigi Xerri; Christopher J Burns; Daniel C Pevear; Denis M Daigle Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: Alyssa R Golden; Melanie R Baxter; James A Karlowsky; Laura Mataseje; Michael R Mulvey; Andrew Walkty; Denice Bay; Frank Schweizer; Philippe R S Lagace-Wiens; Heather J Adam; George G Zhanel Journal: JAC Antimicrob Resist Date: 2022-02-07
Authors: Christian M Gill; Adrian Brink; Chun Yat Chu; Jennifer Coetzee; George Dimopoulos; Clinton Moodley; Christoffel Johannes Opperman; Spyros Pournaras; Fred C Tenover; Isabella A Tickler; Hafsah Deepa Tootla; Sophia Vourli; David P Nicolau Journal: Antimicrob Agents Chemother Date: 2021-07-26 Impact factor: 5.191